Protocol Ledger

NCT06498635 · Phase III · RECRUITING

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Interventional Phase III clinical trial protocol NCT06498635 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-01 Enrollment: 306 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06498635
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)306 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06498635
Protocol FieldVerified Registry Value
NCT IdentifierNCT06498635
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment306 participants (ESTIMATED)
Registered Start Date2025-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI